Targeting lethal prostate cancer in its infancy

  • Risbridger, Gail (Primary Chief Investigator (PCI))
  • Clouston, David (Chief Investigator (CI))
  • Frydenberg, Mark (Chief Investigator (CI))
  • Murphy, Declan G. (Chief Investigator (CI))

Project: Research

Project Details

Project Description

There are two types of prostate cancer. The first requires to hormones to grow and respond well to hormone therapy. The second type doesn’t
respond to hormone therapy and are aggressive. Our work recognizes that there are also tumours which are a mixture of the two types. Current
diagnostic practices fail to detect which patients have mixed tumours, resulting in ineffective treatment. Our work aims to address this issue by
identifying better detection and treatment strategies for these tumours.
Short titleTargeting lethal prostate cancer in its infancy
Effective start/end date1/01/2031/12/22


  • National Health and Medical Research Council (NHMRC) (Australia): A$764,363.50


  • Prostate cancer
  • neuroendocrine differentiation
  • histopathology
  • xenografts
  • cancer treatment